Fagan S C, Kertland H R, Tietjen G E
College of Pharmacy, Wayne State University, Detroit, MI 48202.
Ann Pharmacother. 1994 Apr;28(4):441-3. doi: 10.1177/106002809402800401.
To assess the risk of bleeding complications in patients treated with combination aspirin and heparin for cerebral ischemia.
A retrospective, cohort study.
A large urban teaching hospital.
One hundred charts of stroke patients who had received anticoagulation with or without aspirin therapy were identified from the Stroke Data Bank. Bleeding rates were compared between the two groups.
Forty-two patients who had received heparin and/or warfarin in combination with aspirin were compared with 33 patients who had received anticoagulation alone. The mean duration of anticoagulant therapy was 8.0 and 8.4 days, respectively. Bleeding rates were not different between the two groups: 23.8 percent (10/42) (p = 0.78) and 24.2 percent (8/33), respectively. Although the bleeding rate was substantial, there was only one major bleed (severe epistaxis) occurring in a patient receiving anticoagulation only. No patient had an intracerebral hemorrhage.
Our data suggest that combination antithrombotic therapy is safe in a controlled, inpatient setting.
评估联合使用阿司匹林和肝素治疗脑缺血患者出血并发症的风险。
一项回顾性队列研究。
一家大型城市教学医院。
从卒中数据库中识别出100例接受抗凝治疗(无论是否接受阿司匹林治疗)的卒中患者病历。比较两组的出血率。
将42例接受肝素和/或华法林联合阿司匹林治疗的患者与33例仅接受抗凝治疗的患者进行比较。抗凝治疗的平均持续时间分别为8.0天和8.4天。两组的出血率无差异:分别为23.8%(10/42)(p = 0.78)和24.2%(8/33)。尽管出血率较高,但仅接受抗凝治疗的患者中仅发生1例大出血(严重鼻出血)。无患者发生脑出血。
我们的数据表明,在有控制的住院环境中,联合抗栓治疗是安全的。